SAN DIEGO, CA - April 28, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the key benefits and commercialization avenues of its soon to be published patented enzymatic process for sustainable ibuprofen production. This innovation not only strengthens Quantumzyme’s leadership in green chemistry but also positions the company to capitalize on the global shift toward cleaner, more efficient manufacturing technologies.
The process utilizes a specially engineered enzyme to streamline ibuprofen production, significantly reducing the use of harsh chemicals, solvents, and energy. By replacing traditional multi-step chemical synthesis with a selective biocatalytic transformation, Quantumzyme’s method offers both environmental and economic advantages.
Key Benefits of the Breakthrough Process:
- Environmental Sustainability
- Reduces hazardous waste and solvent usage, in line with global green chemistry principles.
- Lowers the carbon footprint of Active Pharmaceutical Ingredient (API) manufacturing.
- Production Efficiency and Cost Savings:
- Simplifies manufacturing by cutting down on reaction steps and improving yields.
- Decreases raw material and operational costs for pharmaceutical companies.
- Strategic Intellectual Property Strength.
- Secures a competitive position in the sustainable API sector and opens new licensing opportunities.
Quantumzyme plans to offer this soon to be patented process across multiple channels:
- Licensing to major pharmaceutical manufacturers seeking to green their supply chains.
- Direct partnerships for co-development of green production lines.
- Expansion into broader non-steroidal anti-inflammatory drug (NSAID) manufacturing, leveraging the platform’s modular adaptability to related compounds.
“Our enzymatic ibuprofen process exemplifies how cutting-edge science can address real-world industrial challenges,” stated Naveen Kulkarni, CEO of Quantumzyme. “Through strategic commercialization, we aim to help manufacturers achieve regulatory compliance, meet ESG goals, and reduce costs - all while making chemistry greener.”
This breakthrough directly resonates with the scientific momentum sparked by the 2024 Nobel Prize in Chemistry, awarded for advancements in computational enzyme design and protein structure prediction. Like Nobel laureates David Baker, Demis Hassabis, and John Jumper, Quantumzyme leverages artificial intelligence and protein engineering to revolutionize industrial chemistry - delivering sustainable, scalable solutions for the pharmaceutical sector.
By combining green chemistry, computational design, and strategic commercialization, Quantumzyme’s goal is to set new standards for the future of sustainable pharmaceutical production.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
